Related Experiment Video

Updated: Dec 27, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

970

Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma

Mamta Parikh1, Poornima Bajwa2

  • 1Division of Hematology Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA.

Seminars in Nephrology
|March 5, 2020
PubMed

Insights

Immune checkpoint inhibitors and antiangiogenesis agents are key treatments for advanced kidney cancer, improving survival rates. Careful management of side effects is crucial for these effective renal cell carcinoma therapies.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Advanced renal cell carcinoma (RCC) management has been revolutionized by immune checkpoint inhibitors (ICIs).
  • ICIs are approved for both treatment-naive and previously treated (antiangiogenesis agents) advanced RCC patients.
  • Combinations of ICIs and antiangiogenesis agents demonstrate significant efficacy.

Purpose of the Study:

  • To review the role of immune checkpoint inhibitors in advanced renal cell carcinoma.
  • To discuss the combination of ICIs with antiangiogenesis agents for advanced RCC.
  • To highlight the challenges and benefits of these therapeutic strategies.

Main Methods:

  • Review of current literature on immune checkpoint inhibitors and antiangiogenesis agents in advanced renal cell carcinoma.
  • Analysis of clinical trial data regarding response rates and survival outcomes.
  • Discussion of adverse event profiles and management strategies.

Main Results:

  • Combination therapies involving ICIs and antiangiogenesis agents show substantial response rates in advanced RCC.
  • These combination treatments have been shown to prolong overall survival for patients with advanced kidney cancer.
  • Adverse events require careful consideration and management when combining these therapeutic modalities.

Conclusions:

  • Immune checkpoint inhibitors combined with antiangiogenesis agents represent a vital component in treating advanced renal cell carcinoma.
  • Despite management challenges related to adverse events, the survival benefits support their continued use.
  • These therapies offer significant improvements in managing advanced kidney cancer.
Keywords:
Immunotherapycheckpoint inhibitionimmune-related adverse eventskidney cancerrenal cell carcinoma

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
215